Selection of epigenetically privileged HIV-1 proviruses during treatment with panobinostat and interferon-α2a
Cell · 2024-02 · 187 (5) · 1238-1254.e14
DOI: 10.1016/j.cell.2024.01.037 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Cell, 2024-02. Verfasst von Marie Armani-Tourret und 20 weiteren Autor:innen. Beteiligte Einrichtung: Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA. Hauptthemen laut MEDLINE: HIV Infections, HIV-1, Panobinostat, Proviruses. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 111 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NHLBI NIH HHS, NCI NIH HHS.
Abstract (Originalsprache)
CD4+ T cells with latent HIV-1 infection persist despite treatment with antiretroviral agents and represent the main barrier to a cure of HIV-1 infection. Pharmacological disruption of viral latency may expose HIV-1-infected cells to host immune activity, but the clinical efficacy of latency-reversing agents for reducing HIV-1 persistence remains to be proven. Here, we show in a randomized-controlled human clinical trial that the histone deacetylase inhibitor panobinostat, when administered in combination with pegylated interferon-α2a, induces a structural transformation of the HIV-1 reservoir cell pool, characterized by a disproportionate overrepresentation of HIV-1 proviruses integrated in ZNF genes and in chromatin regions with reduced H3K27ac marks, the molecular target sites for panobinostat. By contrast, proviruses near H3K27ac marks were actively selected against, likely due to increased susceptibility to panobinostat. These data suggest that latency-reversing treatment can increase the immunological vulnerability of HIV-1 reservoir cells and accelerate the selection of epigenetically privileged HIV-1 proviruses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
- Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA; Division of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
- Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA 02114, USA.
- Department of Microbiology, University of Pennsylvania, Philadelphia, PA 19104, USA.
- Division of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
- Division of Cardiology, Massachusetts General Hospital, Boston, MA 02114, USA.
Förderung
- NIAID NIH HHS
- NHLBI NIH HHS
- NCI NIH HHS
- NIDA NIH HHS
- NIDDK NIH HHS
- amfAR, The Foundation for AIDS Research
- Novartis Pharmaceuticals Corporation
- National Institutes of Health
Zitieren
APA
Armani-Tourret, M., Gao, C., Hartana, C. A., Sun, W., Carrere, L., Vela, L., Hochroth, A., Bellefroid, M., Sbrolla, A., Shea, K., Flynn, T., Roseto, I., Rassadkina, Y., Lee, C., Giguel, F., Malhotra, R., Bushman, F. D., Gandhi, R. T., Yu, X. G., …, & Lichterfeld, M. (2024). Selection of epigenetically privileged HIV-1 proviruses during treatment with panobinostat and interferon-α2a. Cell, 187(5), 1238-1254.e14. https://doi.org/10.1016/j.cell.2024.01.037
Vancouver
Armani-Tourret M, Gao C, Hartana CA, Sun W, Carrere L, Vela L, et al. Selection of epigenetically privileged HIV-1 proviruses during treatment with panobinostat and interferon-α2a. Cell. 2024;187(5):1238-1254.e14. doi:10.1016/j.cell.2024.01.037
BibTeX
@article{ArmaniTourret2024,
author = {Armani-Tourret, Marie and Gao, Ce and Hartana, Ciputra Adijaya and Sun, WeiWei and Carrere, Leah and Vela, Liliana and Hochroth, Alexander and Bellefroid, Maxime and Sbrolla, Amy and Shea, Katrina and Flynn, Theresa and Roseto, Isabelle and Rassadkina, Yelizaveta and Lee, Carole and Giguel, Francoise and Malhotra, Rajeev and Bushman, Frederic D and Gandhi, Rajesh T and Yu, Xu G and Kuritzkes, Daniel R and Lichterfeld, Mathias},
title = {Selection of epigenetically privileged HIV-1 proviruses during treatment with panobinostat and interferon-α2a},
journal = {Cell},
year = {2024},
volume = {187},
number = {5},
pages = {1238--1254.e14},
doi = {10.1016/j.cell.2024.01.037}
}
EUVIMED